Last C$4.54 CAD
Change Today +0.13 / 2.95%
Volume 100.0
QLT On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ GS
Frankfurt
As of 11:32 AM 11/27/14 All times are local (Market data is delayed by at least 15 minutes).

qlt inc (QLT) Snapshot

Open
C$4.54
Previous Close
C$4.41
Day High
C$4.54
Day Low
C$4.54
52 Week High
01/30/14 - C$7.90
52 Week Low
11/25/14 - C$4.35
Market Cap
232.4M
Average Volume 10 Days
1.8K
EPS TTM
C$-0.49
Shares Outstanding
51.2M
EX-Date
06/28/13
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for QLT INC (QLT)

qlt inc (QLT) Related Businessweek News

No Related Businessweek News Found

qlt inc (QLT) Details

QLT Inc., a biotechnology company, develops and commercializes ocular products that address the unmet medical needs of patients and clinicians worldwide. It focuses on the development of QLT091001, a synthetic retinoid compound, which is in phase Ib retreatment clinical trials for the treatment of leber congenital amaurosis and retinitis pigmentosa; phase Ib clinical trials for the treatment of Retinitis Pigmentosa with autosomal dominant mutation in RPE65; and phase IIa clinical trials for the treatment of impaired dark adaptation. The company was founded in 1981 and is headquartered in Vancouver, Canada.

37 Employees
Last Reported Date: 08/4/14
Founded in 1981

qlt inc (QLT) Top Compensated Officers

Chief Financial Officer
Total Annual Compensation: $233.8K
Compensation as of Fiscal Year 2013.

qlt inc (QLT) Key Developments

QLT Inc. Announces Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

QLT Inc. announced earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net loss of $4.9 million or $0.10 per share, compared with a loss of $7.3 million or $0.14 per share in the same period last year. The operating loss was $5.4 million compared to $7.5 million for the same period in 2013. The net $2.1 million decrease in operating losses is primarily due to lower R&D and restructuring expenses. Basic and diluted net loss per share from continuing operations was $0.10 compared to $0.15 in the same period in 2013. The decrease in loss per share is due to the same factors described above, as well as a $0.4 million income tax recovery recorded in connection with a decrease in the provision for uncertain tax positions due to the expiration of the statute of limitations. Loss from continuing operations before income taxes was $5,358,000 compared to $7,383,000 a year ago. Loss from continuing operations was $4,927,000 compared to $7,492,000 a year ago. For the nine months, the company reported operating loss of $21,750,000 compared to $21,847,000 a year ago. Loss from continuing operations before income taxes was $20,163,000 compared to $19,704,000 a year ago. Loss from continuing operations was $19,969,000 compared to $20,138,000 a year ago. Net loss and comprehensive loss was $20,032,000 compared to $20,022,000 a year ago. Basic and diluted net loss per common share continuing operations was $0.39 compare to $0.40 a year ago. Net loss per common share was $0.39 compared to $0.39 a year ago.

QLT Inc. Appoints Geoffrey F. Cox as Interim Chief Executive Officer

QLT Inc. announced that current QLT Board member, Geoffrey F. Cox, Ph.D., has been appointed interim Chief Executive Officer, effective immediately. Dr. Cox brings more than 35 years of business and scientific leadership in the pharmaceutical and biotechnology industries to QLT, 13 years of which have been as Chairman and CEO of public companies. Dr. Cox will continue in his role as a member of the QLT Board of Directors. In conjunction with Dr. Cox's appointment, the QLT Board has disbanded its Executive Transition Committee. Most recently, Dr. Cox served as an independent consultant to the life sciences industry. From 2001 to 2010, Dr. Cox was Chairman, President and CEO of GTC Biotherapeutics Inc. (now rEVO Biologics), and from 1997 to 2001 he was Chairman, President and CEO of Aronex Pharmaceuticals Inc.

QLT Mulls Acquisitions

QLT Inc. (TSX:QLT) is looking for acquisitions. Jason Aryeh, Chairman of the Board of Directors of QLT said, "We are obviously disappointed that the merger with Auxilium did not complete. In light of this development, we will immediately re-engage in our assessment of all potential strategic options".

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QLT:CN C$4.54 CAD +0.13

QLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for QLT.
View Industry Companies
 

Industry Analysis

QLT

Industry Average

Valuation QLT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QLT INC, please visit www.qltinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.